diagnosis is the differential display 3 gene (DD3) assay also known as the PCA3 (prostate cancer antigen 3) assay and marketed as the PROGENSA TM PCA3 assay [6] . This assay is normalised using prostate-specific antigen (PSA), which has a weak correlation with prostate malignancy. The reported sensitivity and specificity of the PCA3 assay (PCA3 score at a cut-off point of 35) was 58 and 72%, respectively [7] . Although few studies have been conducted on the normalisation of prostatic tumour markers, there are no validated control genes applicable for clinical use. Some of the challenges are: (i) the choice of clinical specimen for molecular testing, (ii) the choice of suitable endogenous control gene(s) for validation and clinical use and (iii) a multicentre evaluation of the above factors.
Urine, serum and prostate biopsies are the main source of clinical specimens for the diagnosis of prostate disease. Nucleic acid-based testing on urine and serum samples may have a reduced sensitivity, especially for well-differentiated prostate carcinomas (low grades) that are organconfined with a low infiltration of malignant cells. Prostatic massage helps to increase the number of exfoliated urine cell sediments. However, in metastatic PCA, 1 5 cells per 7.5 ml of blood are common, which is easily detectable by RQ-PCR [8] . Prostate tissues, either from radical prostatectomy, resection or transrectal ultrasound (TRUS)-guided biopsies are usually fixed for histology. Formalin fixation causes the defragmentation and degradation of nucleic acids. However, the primers for RQ-PCR are designed to amplify short sequences of gene targets (50-150 bp), and such amplicon sizes are available from fixed tissue sections [9, 10] . Molecular profiling using these specimens may assist in the early detection of prostate cancer, risk stratification and the choice of intervention.
The second concern is the choice of suitable endogenous control genes. In 2006, Schmidt et al. [11] reported a quantitative multigene expression profiling of 9 prostate tumour markers using 4 control genes (GAPDH, HPRT, PBGD and TBP) to normalise the gene expression of target amplicons. The GAPDH gene is known to have 60 pseudogenes (www.pseudogenes.org/), which can result in the amplification of non-functional genomic DNA. PBGD has alternative transcriptional start sites [1] , which can produce undetectable transcript variants. HPRT and TBP are also reported to have pseudogenes, and TBP shows a very low expression level which is tissue-dependent [1] . Nonetheless, in the study of Schmidt et al. [11] the TBP gene was chosen because it showed no differential expression between paired tumour and tumour-free samples. Many gene expression studies [1, 2] that are normalised using the ␤ -actin (ACTB) gene even though it is known to have 8 pseudogenes (www.pseudogenes.org/) have been reported. Therefore, the choice of an endogenous control gene for normalising the transcript quantification of prostatic tumour markers is still a crucial issue and a consensus has yet to be reached. The use of a control gene in RQ-PCR informs regarding assay sensitivity and assesses sample quality and analytical reproducibility. This is achieved by the parallel amplification of the target gene and 1 or more control genes.
Three main criteria for selecting control genes are the absence of pseudogenes, a stable expression across different cell types in a tissue and little or no variation due to analytical processing [3] . A multi-centre evaluation is invaluable for ensuring that a standard protocol for RNA extraction, cDNA synthesis, primer design and reporting procedures is followed. Therefore, 3 candidate control genes, i.e. Abelson (ABL1), ␤ -glucuronidase (GUS) and glucose-6-phosphate dehydrogenase (G6PD), were chosen for the evaluation of their suitability for the normalisation of prostate tumour markers in urine cell sediments and FFPE tissue sections. The 3 candidate control genes were chosen because they fulfilled the aforementioned criteria for selecting control genes.
Subjects and Methods
Thirty healthy male participants (mean age 52 years, PSA ! 2.0 ng/ml and no history of prostate disease or urinary symptoms) were recruited at Cranfield University, and ethical approval was obtained from the Cranfield Health Research Ethics Committee. Fifty-three consecutive patients who attended the TRUS prostate biopsy section at Bedford Hospital were recruited, and ethical approval was obtained from the Bedfordshire Research Ethics Committee. One hundred and thirty-eight archived FFPE prostate tissue blocks were obtained from both Cheltenham and Gloucestershire hospitals, and favourable ethical approval was given by the Gloucestershire Research Ethics Committee. Details of the samples and clinical characteristics of the participants are contained in table 1 . were harvested at the exponential phase for stimulation experiments. The steroids, i.e. 17 ␤ -oestradiol, hydrocortisone, 5 ␣ -androstane-17 ␤ -3-one (dihydrotestosterone) and testosterone were purchased from Sigma. All of them were first dissolved in DMSO to a working concentration of 2 m M . Serial dilutions were later made using DCC-FCS-supplemented media for growth inhibition assays.
Prostate Cell Lines and Steroid Hormones

Dose-and Time-Dependent Stimulations
The inhibition concentrations (ICs) of steroid hormones were first determined using a colorimetric sulphorhodamine assay, which has been described in detail previously [12] . The IC 10 and IC 50 values of the steroid hormones were then used to stimulate the cell lines for 12-, 24-, 48-and 72-hour periods. Briefly, 10 6 cells were seeded into each well of a 12-well plate and grown for 12 h at 37 ° C with 5% CO 2 to allow for attachment; hormones were added as well. For each prostate cell line, 2 different doses of the four steroid hormones, i.e. IC 10 and IC 50 doses, were used for the four time intervals (12, 24 , 48 and 72 h), two controls -DMSO treated and no treatment -culture media only were included in all the intervals (resulting in 48 samples of which 16 where controls). The cells were trypsinised and washed in sterile PBS and cell pellets were lysed in 1.0 ml of guanidine isothiocyanate (GITC) buff er (350 l of which was used for RNA extraction).
Clinical Samples
The participants voided 20 ml of early morning urine without prostatic massage. Within 6 h of sample collection, the urine samples were centrifuged at 1,840 g for 10 min, decanted and the cell sediments were washed in 15 ml of sterile PBS (Invitrogen, UK). Cell pellets were lysed in 350 l of GITC buffer for RNA extraction. About 5 ml of venous blood was collected from each of the healthy males (control group) and patients using standard venepuncture techniques. Serum was harvested and serum PSA measured using a Microwell ELISA kit from Diagnostic Automation, Inc., Calabasas, Calif., USA. Tissue blocks were chosen based on pathology reports. The selected samples were: 30 cases of nodular hyperplasia [benign prostatic hyperplasia (BPH)], 96 cases of prostate cancer and 12 cases of non-involved prostate tissueschronic inflammation, no dysplasia and no carcinoma ( table 1 ). T URP = Transurethral resection of the prostate; PCa = prostate carcinoma; RP = radical prostatectomy; N-I = non-involved (no case of malignancy or BPH); PIN = prostatic intraepithelial neoplasia; EMU = early-morning urine without prostatic massage; Cr = control group.
a Patients referred to the urologic clinic due to a raised PSA and/or an abnormal digital rectal examination. They underwent a TRUS biopsy as part of their medical care.
b Healthy subjects did not undergo any biopsy; they were chosen based on a history of no prostate problems and a normal PSA, i.e. a total PSA <2.5 ng/ml. c Medical records of patients whose archived tissue blocks were sampled.
d British whites.
Only tissue blocks with the worst lesions of their category as marked in the corresponding HE slides were sampled for microtomy. The tissue sections were macrodissected. Two pieces of 25-m-thick sections were cut using decontaminated microtome blades, picked onto slides and macrodissected into 2 ml tubes. The tubes were briefly centrifuged and then deparaffinised in 2 washes of 1 ml xylene for 10 min each; the xylene was decanted and the tissue rehydrated by 2 washes in 1 ml of 100% ethanol before allowing the pellets to dry for 5 min on a dry heat block kept at 37 ° C. The tissue pellets were digested overnight in 540 l of ATL tissue lysis buffer and 60 l of proteinase K (Qiagen, UK). The digest was centrifuged for 5 min and the supernatant (containing nucleic acids) was collected. 350 l of the supernatant was used for RNA extraction.
RNA Extraction and cDNA Synthesis
For all samples, 350 l of the cell or tissue lysate was used for RNA extraction using a spin column RNeasy Mini kit (Qiagen). The elution volume was 60 l (50 l of which was used for cDNA synthesis). RNA quality was checked using a BioRad automated electrophoresis system. The average 28S/18S RNA ratio was 1.75 (range 1.60-1.95). The amount of RNA used for cDNA synthesis ranged from 0.7 to 3 g. An equal volume of RNA elution was used in cDNA synthesis. Random primers (at a final concentration of 300 ng per reaction) from Invitrogen, UK, were used for cDNA synthesis using the Moloney murine leukaemic virus reverse transcriptase (Invitrogen) and RNasin (an RNase inhibitor; Promega, UK). The cDNA synthesis was done immediately after RNA extraction.
Real-Time PCR Set-Up
TaqMan chemistries were used in the BioRad CFX96 real-time PCR platform. The sequences of the primers and probes are shown in table 2 . FAM dye was used for ABL1 and GUS, and TET dye for G6PD. For absolute quantification, stable calibrators were used to construct standard curves for reading samples. The ABL1 and G6PD plasmid standards were kind gifts from the laboratory of Dr. Letizia Foroni (Imperial College, London, UK). GUS plasmid was purchased from Ipsogen, Marseille, France. The plasmids were used at 10 1 , 10 2 , 10 3 , 10 4 , 10 5 and10 6 copies per 2.5 l. The number of PCR cycles at which the relative fluorescent signal intensity of a sample or calibrator crosses the threshold line is known as the Ct value [cycle of threshold also known as cycle of quantification (Cq)] and this value is inversely proportional to the starting quantity of the target transcript. Five technical parameters for accepting valid RQ-PCR results were obtained from the following standard curves and amplification plots: (i) the slope of the standard curve which determines PCR efficiency (E) and is related by the formula E = 10 (-1/slope) -1, (ii) the correlation coefficient (R 2 value) which is a measure of the relationship between the Ct value and the log of the starting quantity of the target for a given standard curve, (iii) the y-intercept of the standard curve which is the Ct value that corresponds to a copy of the target molecule, (iv) the difference in the Ct values of duplicate measures ( ⌬ Ct) and (v) the relative fluorescence unit plateau value which is the maximal normalised fluorescent signal at the PCR plateau. The threshold value and baseline were auto-set.
Normalised relative quantification (NRQ) was done for the KLK2 gene using the formula NRQ = E Ct KLK2 /E Ct ABL1 [13] . cDNA from the PNTIA cell line was diluted in tRNA in TE buffer for determining E for the KLK2 quantification. The KLK2 gene is a prostate-specific tissue kallikrein whose protein product (hK2) is a putative prostate tumour marker [14, 15] . The TaqMan Universal 2 ! Master Mix, primers and TaqMan probes were purchased from Applied Biosystems, UK. The thermal profile for the TaqMan assay was 50 ° C for 2 min, an initial denaturation at 95 ° C for 10 min, a cycle denaturation of 95 ° C for 15 s, and annealing and extension at 60 ° C for 1 min for 40 cycles. Data was acquired at all stages. 
Statistical Analysis
The D'Agostino-Pearson omnibus normality test was performed on the data sets, and Kruskal-Wallis and Dunn's multiple comparisons tests were performed for the analysis of variance (ANOVA). GraphPad Prism version 4.02 software (www. graphpad.com) was used.
Results
The IC 10 From the amplification plots and standard curves (not shown), our slope range was -3.30 to -3.60, R 2 values were 1 0.99, the y-intercept was ^ 40, the ⌬ Ct was ! 1.0 and the relative fluorescence at plateau value was consistently ^ 1,000.
The transcript levels of ABL1 in the FFPE prostate tissue sections are shown in figure 1 a. In the cell lines the median value of ABL1 copies was 1. ). There was no significant difference in the ABL1 transcript copies when cell lines were compared to one another or when the clinical samples were compared to one another.
The GUS transcript number in the FFPE prostate tissue sections is shown in figure 1 The mean value of the ABL1 transcript number was related to that of GUS by a ratio of 1.19 and to that of G6PD by a ratio of 0.36 in the cell lines, and by ratios of 1.03 and 0.82, respectively, in the clinical samples. Conversely, the mean value of the G6PD transcript number related to that of GUS by a ratio of 3.30 and to that of ABL1 by a ratio of 1.25 in the cell lines. The mean ABL1 transcript number lies between those of GUS and G6PD.
The transcript levels of all the control genes in the exfoliated urine cells of healthy males (n = 30) and the patient group who attended the TRUS-guided prostate biopsy section (n = 53) are given in figure 1 c. The GUS transcript number differed significantly between the healthy controls and the patient group (p ! 0.05). The serum PSA levels of the healthy controls, TRUS biopsy patients and FFPE cases are given in figure 1 d. Only 6 (4.3%) FFPE patients had a PSA level ! 2.50 ng/ml, 5 of whom were BPH cases and 1 of whom was a chronic inflammation case. In the TRUS biopsy cohort, only 1 patient (a non-involved case) had a PSA level ! 2.50 ng/ml. There was a significant difference in serum PSA between the healthy controls and the TRUS biopsy patients (p ! 0.001) and between the healthy controls and the FFPE cases (p ! 0.001).
The NRQ of KLK2 in the clinical specimens is shown in figure 1 e. There was no difference in the NRQ of KLK2 determined using ABL1 alone compared to that determined using the geometric mean of the 3 control genes. The normalised KLK2 transcript level was significantly lower in benign and malignant cases compared to healthy controls (p ! 0.05). KLK2 is a prostate-specific tissue kallikrein.
The effect of sample age on ABL1 transcript copies in archived FFPE tissue materials for all cases (normal, BPH and prostate cancer) is shown in figure 1 f. There was a significant difference in ABL1 copies between cases from 2006-2007 and 2008 samples (p ! 0.001). Aged samples had a reduced ABL1 transcript number. Similar results were obtained for GUS and G6PD (data not shown).
Discussion
Crucial for the routine use of RQ-PCR for diagnostic pathology is the choice of control genes for normalising results and quality control. The ABL1, GUS and G6PD genes were expressed in all the samples. G6PD and ABL1 gene expressions were more stable than that of GUS in different prostate specimen types but G6PD and GUS differed significantly. Previous reports [1, 2] showed that ABL1 transcript numbers were more stable than those of GUS in leukaemic blood samples. Unlike other prostate control genes, i.e. GAPDH, HPRT, PBGD, TBP, 18S rRNA and ACTB previously reported [1, 10, 11] , the ABL1 gene has no known pseudogenes. In this study, the ABL1 transcript number showed no significant variation between prostate tumour and tumour-free samples. The relative ratio of ABL1 to GUS and of ABL1 to G6PD was similar in both the cell lines and the clinical samples. ABL1 was the most stable of the 3 control genes in terms of expression level (transcript number). Its transcript number correlated with the cell number in different specimen types. A comparison of the control genes' transcript numbers in aged FFPE tissues showed that more recently processed samples (2008 cases) were significantly better than older samples for normal, BPH and prostate cancer cases (p ! 0.001) ( fig. 1 f) . Another comparison showed that sample handling (oestradiol treatment) affected the control gene level. Higher doses of oestradiol caused a significant reduction (p ! 0.01) in the copies of control genes due to a reduced cell number (data not shown). Therefore, the ABL1 gene was much better than previously reported control genes.
Biologically, the regulation of housekeeping genes reflects variations in normal cellular activities. The decrease in the control gene transcript number as a result of poor sample quality necessitates a consensus cut-off value for assessing sample quality in both the exfoliated There was a significant difference in transcript number between prostate cancer cases and non-involved cases (p ! 0.05, KruskalWallis test). c Transcript levels of ABL1, G6PD and GUS in the exfoliated urine cells of patients and healthy males (control group). There was also a significant difference in GUS transcript number between patients and healthy controls (p ! 0.05, KruskalWallis test). Px = Patients; Cr = control group. d Serum PSA in the healthy control group, prospective patients and archived FFPE cases (PSA values for FFPE cases were based on clinical notes at the time of referral). PSA was significantly lower in the control group (p ! 0.05, Kruskal-Wallis test). e NRQ of KLK2 in the exfoliated urine cells of the patients and healthy controls. There is no significant difference. The NRQ of KLK2 was significantly lower in the patient group (benign and malignant cases) compared to the healthy subjects (p ! 0.05). PIN = Prostatic intraepithelial neoplasia. f Sample age affected the transcript levels of the control genes. Most recently processed FFPE samples for all cases (normal, BPH and prostate cancer) had a significantly higher ABL1 value compared to 1-and 2-year-old samples. Similar results were obtained for GUS and G6PD.
urine cells and the FFPE materials. There is a requirement to establish baseline values for the ABL1 transcript number in both specimen types [16] . Conventionally, 10 4 copies of ABL1 per 2.5 l cDNA is accepted as a consensus cut-off value for good sample quality [3, 16] . However, this cut-off point was determined with blood samples. Currently there is no consensus cut-off value for prostate tissues. By using ABL1 as a stable control gene for prostate tissue, a cut-off value could be established from various laboratories using large sample sizes. The control gene level affects RQ-PCR assay sensitivity; therefore, the interpretation of results must be treated with caution when the control gene level is reduced. The primary task is to establish the ABL1 transcript number at which an FFPE material may be considered a good sample for the RQ-PCR of prostatic tumour markers with the same criteria affecting tests done on exfoliated urine cells with or without prostatic massage. Another point is the adherence to a set of analytical guidelines such as, for example, the 5 parameters for assessing a valid RQ-PCR as reported in the Results section. In addition, it is important that a standard protocol for RNA extraction, cDNA synthesis and reporting guidelines also be adhered to [16] . A single control gene (ABL1) facilitates the inter-laboratory comparison of results, which is of paramount importance to the clinical use of molecular diagnostics. However, control samples which can be used across different laboratories would also ensure compliance with good laboratory practice [16] . Our study supports the use of the ABL1 control gene for future validations. The normalisation of molecular tests for genes such as TMPRSS2 fusion genes, PSA, AR, oestrogen receptors, PCA3 and CD44 using the ABL1 gene may assist the diagnosis, risk stratification and prognostication of prostate tumours.
